1. Home
  2. NAK vs MGTX Comparison

NAK vs MGTX Comparison

Compare NAK & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Northern Dynasty Minerals Ltd.

NAK

Northern Dynasty Minerals Ltd.

HOLD

Current Price

$1.78

Market Cap

1.2B

ML Signal

HOLD

Logo MeiraGTx Holdings plc

MGTX

MeiraGTx Holdings plc

HOLD

Current Price

$14.80

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAK
MGTX
Founded
1983
2015
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
2002
2018

Fundamental Metrics

Financial Performance
Metric
NAK
MGTX
Price
$1.78
$14.80
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
7
Target Price
$2.50
$24.57
AVG Volume (30 Days)
4.0M
543.8K
Earning Date
05-15-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.02
EPS
N/A
1.30
Revenue
N/A
$81,391,000.00
Revenue This Year
N/A
$141.38
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$11.03
Revenue Growth
N/A
144.57
52 Week Low
$0.81
$6.62
52 Week High
$2.98
$15.35

Technical Indicators

Market Signals
Indicator
NAK
MGTX
Relative Strength Index (RSI) 57.75 68.43
Support Level $1.32 $7.04
Resistance Level $1.79 $15.35
Average True Range (ATR) 0.08 0.73
MACD 0.02 0.19
Stochastic Oscillator 96.00 94.20

Price Performance

Historical Comparison
NAK
MGTX

About NAK Northern Dynasty Minerals Ltd.

Northern Dynasty Minerals Ltd is a mineral exploration company. It has a single operating segment of acquisition, exploration, and development of mineral properties. Its core asset is the Pebble Project located in Alaska, USA. The Pebble project is seeking to develop a deposit of copper, gold, molybdenum, and silver into a modern mining operation.

About MGTX MeiraGTx Holdings plc

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.

Share on Social Networks: